3.1 The Bone Mass Measurement Act: Covered Indications and Coding

3.1 The Bone Mass Measurement Act: Covered Indications and Coding

Quick Answer: The Bone Mass Measurement Act created Medicare Part B coverage of bone density testing, codified at 42 CFR 410.31 and effective July 1, 1998. Coverage requires a physician order, appropriate supervision, FDA-cleared equipment, and membership in one of five qualifying categories. The standard frequency is one covered measurement when at least 23 months have passed since the month of the last one, with two defined exceptions.

Why the Technologist Owns This Topic

Coverage rules are a named ARRT content item, and for a working reason: the technologist is usually the last person to see the requisition before the scan happens. If the order lacks a qualifying indication, or if the patient's last scan was 14 months ago and no exception applies, the scan will be performed and then denied. The patient receives the radiation, the facility absorbs the cost, and the technologist is the person who could have caught it.

Statutory Background

The Bone Mass Measurement Act was enacted as part of the Balanced Budget Act of 1997 and implemented through the regulation at 42 CFR 410.31, effective July 1, 1998. Before it, Medicare coverage of bone density testing varied by carrier. The Act standardized coverage nationally and, critically, defined it by patient category rather than by diagnosis code alone.

The regulation defines a bone mass measurement as a radiologic, radioisotopic, or other procedure performed to identify bone mass, detect bone loss, or determine bone quality, using a bone densitometer or bone sonometer system that has been cleared or approved by the FDA, and that includes a physician's interpretation of the results.

Three conditions apply to every covered study regardless of category:

1. It is ordered by a physician or qualified nonphysician practitioner who is treating the beneficiary.
2. It is performed under appropriate physician supervision.
3. It is reasonable and necessary for diagnosing and treating the beneficiary's condition.

The Five Qualifying Categories

Two details in this list generate exam items:

• Category 3 is 5.0 mg of prednisone equivalent or greater, averaged daily, for more than 3 months. The same threshold appears in the FRAX glucocorticoid input and in clinical guidelines for glucocorticoid-induced osteoporosis, which is convenient — one number covers three topics. It is an average, so alternating high-dose and low-dose regimens still qualify if the average clears 5.0 mg.
• Category 4 specifies primary hyperparathyroidism. Secondary hyperparathyroidism, which is common in chronic kidney disease and vitamin D deficiency, is not the named category. Primary hyperparathyroidism preferentially attacks cortical bone, which is why forearm imaging matters in these patients.

Note also what is absent: there is no age-based screening category. A healthy 68-year-old woman with no risk factors is covered under universal screening guidance from professional societies, but the Medicare category she satisfies is category 1 only if her physician documents estrogen deficiency and clinical risk. Coverage categories and clinical practice guidelines are related but not identical, and confusing them is a classic distractor.

Frequency: The 23-Month Standard

Medicare may cover a bone mass measurement when at least 23 months have passed since the month the last bone mass measurement was performed.

The number is 23, not 24. The regulation counts from the month of the prior study, and the 23-month construction means a patient scanned in March of one year becomes eligible again in February two years later rather than in March. In practice this gives scheduling a one-month cushion and prevents denials caused by a study drifting a few days early.

Exceptions Permitting More Frequent Testing

The regulation allows measurement more often than every 23 months when medically necessary, and names two circumstances:

1. Monitoring beneficiaries on long-term glucocorticoid therapy of more than 3 months' duration. Glucocorticoid-induced bone loss is fastest in the first 6 to 12 months of treatment, so annual or semiannual monitoring is clinically justified.
2. Confirming a baseline measurement to permit future monitoring, when the initial measurement was not performed with dual-energy x-ray absorptiometry — that is, when the baseline used a different technology such as peripheral DXA or quantitative ultrasound and a central DXA baseline is needed before serial monitoring can be meaningful.

The second exception is the one technologists encounter most often. A patient screened at a health fair with a heel sonometer arrives with an abnormal result; a confirmatory central DXA is covered even though a "bone mass measurement" was performed weeks earlier, because the two technologies are not comparable and no valid baseline exists.

Practical Documentation and Coding Notes

• Bone density services are reported with dedicated CPT codes distinguishing axial DXA (lumbar spine and hip), appendicular DXA (forearm, heel), and vertebral fracture assessment. Facilities bill technical and professional components; the technologist's role is ensuring the documentation supports the study actually performed.
• The scan performed must match the scan ordered. If the order specifies axial DXA and the spine is unanalyzable, adding the forearm requires contacting the ordering provider rather than substituting silently.
• Record the qualifying indication. The requisition should carry the category or the supporting diagnosis; a requisition reading only "osteoporosis screening" is a frequent denial source.
• Document prior study dates. Knowing the month of the last measurement, and on which device it was performed, determines both coverage and whether serial comparison is even valid.
• A patient may still elect a non-covered scan as a self-pay study; the facility's Advance Beneficiary Notice process, not the technologist, governs that conversation.